Andreas von Poblotzki

Andreas von Poblotzki has a diverse work experience spanning over several companies and roles. Andreas currently holds the position of Country Manager Germany & Commercial Lead DACH at Blueprint Medicines since 2022. Prior to that, they were the Director of Marketing & Sales DACH at Blueprint Medicines from 2021 to 2022.

Before joining Blueprint Medicines, Andreas worked at Vertex Pharmaceuticals where they held various roles including Marketing Director from 2020 to 2021, Interim Country Manager from 2019 to 2020, and Commercial Director from 2014 to 2020.

Andreas also has experience as a Business Consultant at avp consulting in 2014.

At Gilead Sciences, Andreas served as the Business Unit Director Hepatology from 2012 to 2014. Andreas was responsible for launching SOVALDI (Sofosbuvir) in Hepatitis C, expanding market leadership in Hepatitis B, and leading the BU for specialist care in Hepatitis B, Cystic fibrosis, and Antifungal business from 2010 to 2012.

Andreas previously worked at GSK as the Director of Marketing & Sales for CNS/Anesthesia from 2009 to 2010 and as the Head of Marketing for Vaccines from 2001 to 2009. Andreas successfully launched key products including Priorix Tetra, Cervarix, and Rotarix.

Andreas began their career at SmithKlineBeecham in 1996, holding roles such as Senior Product Manager and Area Sales Manager before working as a Product Manager at SmithKlineBeecham Biologicals in 1999.

Overall, Andreas von Poblotzki has accumulated extensive experience and expertise in marketing, sales, and business leadership within the pharmaceutical industry.

Andreas von Poblotzki earned a Doctor of Philosophy (Ph.D.) degree in Biologie, allgemein from the University of Regensburg, completing the program from 1992 to 1995. Andreas also obtained a Diploma in Biologie, allgemein from Ludwig-Maximilians-Universität München, although the dates of enrollment and completion are unknown.